Resolution Therapeutics has partnered with Blood Centers of America to deliver RTX001, an autologous macrophage therapy for end-stage liver disease, through community apheresis and cell-processing infrastructure rather than specialized transplant centers. The therapy reprograms the patient's own immune cells to favor tissue repair over inflammation, and requires no preconditioning chemotherapy or extended hospital monitoring. For a population in which 37% die within two years of first decompensation and only 5% receive a transplant, proximity of care is a determinant of survival.
Key Points
- Macrophage therapy restarts liver repair without preconditioning chemotherapy
- Only 5% of decompensated patients receive a transplant
- 400 apheresis machines across 43 states enable community delivery
Longevity Analysis
Regenerative capacity in a scarred liver is not simply absent — it is suppressed by a chronic inflammatory state, and redirecting macrophages toward their repair phenotype targets that imbalance rather than substituting for lost function. The organ that governs detoxification and metabolic clearance rarely fails in isolation; its collapse cascades through circulation, immune signaling and energy metabolism. Equally significant is the delivery architecture: a therapy that cannot reach patients too ill to travel produces no survival benefit, making logistics a biological variable in its own right.
Original published by Longevity.Technology, by Kyle Umipig.